Impact of diabetes on the natural history of tuberculosis

Diabetes Research and Clinical Practice

Volumn 106, Issue 2, 2014, Pages 191-199

  Restrepo, Blanca I ^a   Schlesinger, Larry S ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Diabetes; Hyperglycemia; Immunity; Review; Tuberculosis

Indexed keywords

ADAPTIVE IMMUNITY; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; EXTRAPULMONARY TUBERCULOSIS; HISTORY; HOST; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOLOGY; INFECTION RISK; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; POSTPRIMARY TUBERCULOSIS; PRIMARY TUBERCULOSIS; PUBLIC HEALTH; REVIEW; SYMPTOM; TREATMENT OUTCOME; TUBERCULOSIS; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH; MORBIDITY; RISK FACTOR; TRENDS;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; HUMANS; MORBIDITY; PUBLIC HEALTH; RISK FACTORS; TUBERCULOSIS;

EID: 84920694101     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.06.011     Document Type: Review

References (80)

1. World Health Organization Global Tuberculosis Report 2013, http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf.
2. Fox G.J., Menzies D. Epidemiology of tuberculosis immunology. Adv Exp Med Biol 2013, 783:1-32.
3. Rieder H.L. The dynamics of tuberculosis epidemiology. Indian J Tuberc 2014, 61(1):19-29.
4. Getahun H., Gunneberg C., Granich R., Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010, 50(Suppl. 3):S201-S207.
5. Morton R. Phthisiologia, Or a Treatise of Consumptions 1694, Sam. Smith and Benj. Walford, London.
6. Banyai A.L. Diabetes and pulmonary tuberculosis. Am Rev Tuberc 1931, 24:650-667.
7. Oscarsson P.N., Silwer H. Incidence of pulmonary tuberculosis among diabetics. Acta Med Scand 1958, 335:23-48.
8. Root H.F. The association of diabetes and tuberculosis. N Engl J Med 1934, 210:1-13.
9. Chen L., Magliano D.J., Zimmet P.Z. The worldwide epidemiology of type 2 diabetes mellitus - present and future perspectives. Nat Rev Endocrinol 2012, 8(4):228-236.
10. International Diabetes Federation Diabetes Atlas 2014, Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf [cited November 2012]. http://www.diabetesatlas.org/.
11. Dye C. Global epidemiology of tuberculosis. Lancet 2006, 367(9514):938-940.
12. Jeon C.Y., Harries A.D., Baker M.A., Hart J.E., Kapur A., Lonnroth K., et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010, 15(11):1300-1314.
13. Ottmani S.E., Murray M.B., Jeon C.Y., Baker M.A., Kapur A., Lonnroth K., et al. Consultation meeting on tuberculosis and diabetes mellitus: meeting summary and recommendations. Int J Tuberc Lung Dis 2010, 14(12):1513-1517.
14. Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
15. Guirado E., Schlesinger L.S., Kaplan G. Macrophages in tuberculosis: friend or foe. Semin Immunopathol 2013, 35(5):563-583.
16. Nicod L.P. Immunology of tuberculosis. Swiss Med Wkly 2007, 137(25-26):357-362.
17. Fabri M., Stenger S., Shin D.M., Yuk J.M., Liu P.T., Realegeno S., et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011, 3(104):104ra102.
18. Restrepo B.I., Schlesinger L.S. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis (Edinb) 2013, 93(S1):S10-S14.
19. Martinez N., Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014, 44(3):617-626.
20. Gomez D.I., Twahirwa M., Schlesinger L.S., Restrepo B.I. Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control. Tuberculosis 2013, 93(2):192-197.
21. Restrepo B.I., Twahirwa M., Rahbar M.H., Schlesinger L.S. Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLOS ONE 2014, 9(3):e92977.
22. Vallerskog T., Martens G.W., Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J Immunol 2010, 184(11):6275-6282.
23. Restrepo B.I., Fisher-Hoch S., Pino P., Salinas A., Rahbar M.H., Mora F., et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008, 47:634-641.
24. Kumar N.P., Sridhar R., Banurekha V.V., Jawahar M.S., Nutman T.B., Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis 2013, 208(5):739-748.
25. Walsh M., Camerlin A., Miles R., Pino P., Martinez P., Mora-Guzman F., et al. Sensitivity of Interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis 2010, 15(2):179-184.
26. Wang C.H., Yu C.T., Lin H.C., Liu C.Y., Kuo H.P. Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis. Tuber Lung Dis 1999, 79(4):235-242.
27. Sun Q., Zhang Q., Xiao H., Cui H., Su B. Significance of the frequency of CD4+CD25+C. Respirology 2012, 17(5):876-882.
28. Martens G.W., Arikan M.C., Lee J., Ren F., Greiner D., Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol 2007, 37:518-524.
29. Yamashiro S., Kawakami K., Uezu K., Kinjo T., Miyagi K., Nakamura K., et al. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin Exp Immunol 2005, 139(1):57-64.
30. Boucot K.R., Dillon E.S., Cooper D.A., Meier P., Richardson R. Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc 1952, 65(1-2):1-50.
31. Jeon C.Y., Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5(7):1091-1101.
32. Leegaard A., Riis A., Kornum J.B., Prahl J.B., Thomsen V.O., Sorensen H.T., et al. Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care 2011, 34(12):2530-2535.
33. Leung C.C., Lam T.H., Chan W.M., Yew W.W., Ho K.S., Leung G.M., et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 2008, 167(12):1486-1494.
34. Dobler C.C., Flack J.R., Marks G.B. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open 2012, 2(1):e000666.
35. Baker M.A., Lin H.H., Chang H.Y., Murray M.B. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012, 54(6):818-825.
36. Restrepo B.I., Camerlin A., Rahbar M., Restrepo M., Zarate I., Wing R., et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis patients. Bull World Health Organ 2011, 89:352-359.
37. Reed G.W., Choi H., Lee S.Y., Lee M., Kim Y., Park H., et al. Impact of diabetes and smoking on mortality in tuberculosis. PLOS ONE 2013, 8(2):e58044.
38. Walker C., Unwin N. Estimates of the impact of diabetes on the incidence of pulmonary tuberculosis in different ethnic groups in England. Thorax 2010, 65:578-581.
39. Stevenson C.R., Forouhi N.G., Roglic G., Williams B.G., Lauer J.A., Dye C., et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007, 7(147):234.
40. Ponce-De-Leon A., Garcia-Garcia MdL, Garcia-Sancho M.C., Gomez-Perez F.J., Valdespino-Gomez J.L., Olaiz-Fernandez G., et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004, 27(7):1584-1590.
41. Jeon C.Y., Murray M.B., Baker M.A. Managing tuberculosis in patients with diabetes mellitus: why we care and what we know. Expert Rev Anti Infect Ther 2012, 10(8):863-868.
42. Jimenez-Corona M.E., Cruz-Hervert L.P., Garcia-Garcia L., Ferreyra-Reyes L., Delgado-Sanchez G., Bobadilla-del-Valle M., et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax 2013, 68(3):214-220.
43. Jorgensen M.E., Faurholt-Jepsen D. Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review. Curr Diab Rep 2014, 14(7):505.
44. Viswanathan V., Vigneswari A., Selvan K., Satyavani K., Rajeswari R., Kapur A. Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis - a report from South India. J Diabetes Complicat 2014, 28(2):162-165.
45. Baker M.A., Harries A.D., Jeon C.Y., Hart J.E., Kapur A., Lonnroth K., et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011, 9:81.
46. Koziel H., Koziel M.J. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am 1995, 9(1):65-96.
47. WHO, International Union Against TB Lung Disease Collaborative Framework for Care and Control of Tuberculosis and Diabetes 2011.
48. Requena-Mendez A., Davies G., Ardrey A., Jave O., Lopez-Romero S.L., Ward S.A., et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother 2012, 56(5):2357-2363.
49. Nijland H.M., Ruslami R., Stalenhoef J.E., Nelwan E.J., Alisjahbana B., Nelwan R.H., et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43(7):848-854.
50. Babalik A., Ulus I.H., Bakirci N., Kuyucu T., Arpag H., Dagyildizi L., et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob Agents Chemother 2013, 57(11):5740-5742.
51. Ruslami R., Nijland H.M., Adhiarta I.G., Kariadi S.H., Alisjahbana B., Aarnoutse R.E., et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010, 54(3):1068-1074.
52. Fisher-Hoch S.P., Whitney E., McCormick J.B., Crespo G., Smith B., Rahbar M.H., et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008, 40(11-12):888-893.
53. Lee M.S., Leung C.C., Kam K.M., Wong M.Y., Leung M.C., Tam C.M., et al. Early and late tuberculosis risks among close contacts in Hong Kong. Int J Tuberc Lung Dis 2008, 12(3):281-287.
54. Perez-Guzman C., Torres-Cruz A., Villarreal-Velarde H., Vargas M.H. Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes. Am J Respir Crit Care Med 2000, 162(5):1738-1740.
55. Bacakoglu F., Basoglu O.O., Cok G., Sayiner A., Ates M. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001, 68(6):595-600.
56. Rawat J., Sindhwani G., Biswas D. Effect of age on presentation with diabetes: comparison of nondiabetic patients with new smear-positive pulmonary tuberculosis patients. Lung India 2011, 28(3):187-190.
57. Faurholt-Jepsen D., Aabye M.G., Jensen A.V., Range N., PrayGod G., Jeremiah K., et al. Diabetes is associated with lower tuberculosis antigen-specific interferon gamma release in Tanzanian tuberculosis patients and non-tuberculosis controls. Scand J Infect Dis 2014, 46(5):384-391.
58. Syed Ahamed K.B., Raman B., Thomas A., Perumal V., Raja A. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS ONE 2010, 5(2):e9051.
59. Jung J.Y., Lim J.E., Lee H.J., Kim Y.M., Cho S.N., Kim S.K., et al. Questionable role of interferon-gamma assays for smear-negative pulmonary TB in immunocompromised patients. J Infect 2012, 64(2):188-196.
60. Leeds I.L., Magee M.J., Kurbatova E.V., del R.C., Blumberg H.M., Leonard M.K., et al. Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis 2012, 55(1):75-81.
61. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005, 44(6):714-720.
62. Reis-Santos B., Locatelli R., Horta B.L., Faerstein E., Sanchez M.N., Riley L.W., et al. Socio-demographic and clinical differences in subjects with tuberculosis with and without diabetes mellitus in Brazil - a multivariate analysis. PLOS ONE 2013, 8(4):e62604.
63. Restrepo B.I., Fisher-Hoch S.P., Crespo J.G., Whitney E., Perez A., Smith B., et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007, 135(3):483-491.
64. Lin J.N., Lai C.H., Chen Y.H., Lee S.S., Tsai S.S., Huang C.K., et al. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. Int J Tuberc Lung Dis 2009, 13(5):620-625.
65. Viswanathan V., Kumpatla S., Aravindalochanan V., Rajan R., Chinnasamy C., Srinivasan R., et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS ONE 2012, 7(7):e41367.
66. Kumar N., Nutman T., Babu S. Expansion of pathogen-specific Th1 and Th17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis 2013, 208:739-748.
67. Guirado E., Schlesinger L.S. Modeling the Mycobacterium tuberculosis granuloma - the critical battlefield in host immunity and disease. Front Immunol 2013, 4:98.
68. Russell D.G. Who puts the tubercle in tuberculosis?. Nat Rev Microbiol 2007, 5(1):39-47.
69. Moran A., Harbour D.V., Teeter L.D., Musser J.M., Graviss E.A. Is alcohol use associated with cavitary disease in tuberculosis?. Alcohol Clin Exp Res 2007, 31(1):33-38.
70. Chiang C.Y., Lee J.J., Chien S.T., Enarson D.A., Chang Y.C., Chen Y.T., et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLOS ONE 2014, 9(4):e93397.
71. Perlman D.C., El-Sadr W.M., Nelson E.T., Matts J.P., Telzak E.E., Salomon N., et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997, 25(2):242-246.
72. Peter J.G., Theron G., Singh N., Singh A., Dheda K. Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. Eur Respir J 2014, 43(1):185-194.
73. Behr M.A., Warren S.A., Salamon H., Hopewell P.C., Ponce de L.A., Daley C.L., et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999, 353(9151):444-449.
74. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
75. Hirsch I.B., Brownlee M. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007, 30(1):186-187.
76. Hirsch I.B., Brownlee M. Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. J Am Med Assoc 2010, 303(22):2291-2292.
77. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 2006, 295(14):1681-1687.
78. Monnier L., Colette C., Leiter L., Ceriello A., Hanefeld M., Owens D., et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007, 30(1):185-186.
79. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008, 205(10):2409-2417.
80. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107(9):1058-1070.